Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (clinicaltrials.gov) - Sep 30, 2026 - P3 | N=300 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Jun 2029 | Trial primary completion date: Dec 2026 ➔ Jun 2029
Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|